What Is Alpha-MSH? Benefits, Research & Safety
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
UK summary: Endogenous melanocortin peptide. Afamelanotide (Scenesse), a stable α-MSH analogue, is licensed in some jurisdictions for erythropoietic protoporphyria; native α-MSH is not a UK medicine for cosmetic or anti-inflammatory use.
Quick Facts
Overview
Alpha-MSH — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous melanocortin peptide. Afamelanotide (Scenesse), a stable α-MSH analogue, is licensed in some jurisdictions for erythropoietic protoporphyria; native α-MSH is not a UK medicine for cosmetic or anti-inflammatory use.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.
- EU: Afamelanotide approved for erythropoietic protoporphyria.
- Notes: α-MSH itself is not used clinically. Synthetic analogues have various regulatory statuses: afamelanotide is approved for EPP; bremelanotide for HSDD (US only). Melanotan products are not approved.
05Approved medical uses
- Erythropoietic protoporphyria (afamelanotide / Scenesse — licensed in EU and US for this rare condition only).
06Unapproved / promotional claims
- Cosmetic tanning.
- Anti-inflammatory wellness supplement.
- Safer than Melanotan II.
07Common internet claims
- Marketed by some grey-market vendors as 'native' melanocortin analogue.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Safer tanning agent than Melanotan II” | E | No | High | Afamelanotide is licensed only for a rare photodermatosis. Native α-MSH and analogues are not approved for cosmetic tanning. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Nausea, fatigue, skin hyperpigmentation, melanocytic nevi changes (need dermatology surveillance with afamelanotide).
- MHRA has warned against unlicensed melanotan products.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Afamelanotide approved for erythropoietic protoporphyria.
15What this page cannot tell you
- Whether a grey-market 'alpha-MSH' product contains the labelled peptide.
- Long-term safety in healthy adults outside the licensed EPP indication.
16Last reviewed
17Citation quality score
18Research gaps
- Outside EPP, therapeutic development is limited.
19Safer alternatives / established care pathways
- Dermatology referral for genuine pigmentation concerns.
- Sunscreen and self-tanning products for cosmetic concerns.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate dermatology consultation rather than a peptide self-experiment?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Skin pigmentation (therapeutic in certain photosensitivity disorders)
- 2Potent anti-inflammatory effects across multiple systems
- 3Fever reduction (antipyretic)
- 4Appetite regulation
- 5Effects on sexual function
- 6Potential protection in inflammatory bowel disease, arthritis, and other conditions
- 7Basis for approved medications (afamelanotide, bremelanotide)
Claim vs Evidence
How popular claims about Alpha-MSH stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Safer tanning agent than Melanotan II” | E | No | High | Afamelanotide is licensed only for a rare photodermatosis. Native α-MSH and analogues are not approved for cosmetic tanning. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Not administered as native α-MSH; see synthetic analogues |
| Frequency | N/A for native peptide |
| Duration | N/A |
| Notes | Native α-MSH is not used therapeutically due to short half-life. Synthetic analogues (afamelanotide, bremelanotide, melanotan) are used clinically or in research. These have modified structures for improved stability. |
Administration Routes
Routes studied in research settings (educational only):
- Native α-MSH: Not administered therapeutically
- Analogues: Subcutaneous injection, implant (afamelanotide)
| Half-Life | Stability |
|---|---|
| Very short; minutes (native α-MSH) | Rapidly degraded; analogues engineered for stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- See synthetic analogues for side effect profiles
- Nausea (with some analogues)
- Skin darkening
- Flushing
Rare Risks & Concerns
- Changes to moles (with tanning analogues)
- Theoretical melanoma concerns
- Unknown long-term effects of chronic melanocortin stimulation
Contraindications
- History of melanoma (for tanning analogues)
- Multiple atypical moles
- Pregnancy
- See specific analogue information
UK & EU Regulatory Context
🇬🇧 United Kingdom
Native α-MSH not licensed. Afamelanotide (Scenesse) approved for EPP.
🇪🇺 European Union
Afamelanotide approved for erythropoietic protoporphyria.
Clinical Studies Summary
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.
It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.
Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.
Collectively, these data suggest that targeting MC1R could serve as an approach in the treatment of metastatic melanoma. In this review, we explore the molecular biology of α-MSH with particular emphasis into its tumor-related properties, whilst elaborating the experimental evidence currently available regarding the interplay between α-MSH/MC1R axis, melanoma and antitumor strategies.
Bremelanotide: First Approval.
Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.
Peptides and aging: Their role in anorexia and memory.
A number of centrally acting neuropeptides have also been shown to modulate cognitive processes. Amyloid-beta peptide in physiological levels is a memory enhancer, while in high (pathological) levels, it plays a key role in the development of Alzheimer's disease.
Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide.
Similar to α-MSH's anti-inflammatory properties, its C-terminal residues also exhibit antimicrobial activity parallel to that of the entire peptide. This review is focused on the current findings regarding the direct antimicrobial potential and immunomodulatory mechanism of α-MSH and its C-terminal fragments, with particular emphasis on the prospects of α-MSH based peptides as a strong anti-infective agent.
Gene therapy for noninfectious uveitis.
To date, gene therapy approaches using interleukin-10, interleukin-1 receptor antagonist, interferon-alpha, soluble TNF-alpha receptors, and alpha-MSH gene transfer have been used successfully to attenuate experimental animal models of uveitis. This review evaluates these preclinical studies, considers the route to clinical application, and explores future targets and approaches.
Registered Trials & Regulatory Status
1 of 2 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes
Status: Unknown · 13 participants · Dasman Diabetes Institute
Conditions: Type 2 Diabetes Mellitus
Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders
Status: Completed · 211 participants · University Hospital, Rouen
Conditions: Eating Disorder
Alpha MSH in Ocular Disease
Status: Completed · 54 participants · Duke University
Conditions: Advanced Dry Macular Degeneration
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Alpha-MSH?
Source research-grade Alpha-MSH from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Alpha-MSH
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate dermatology consultation rather than a peptide self-experiment?
UK regulatory & safety context
Related Peptides
Melanotan II
A synthetic analogue of alpha-melanocyte stimulating hormone researched for tanning effects and sexual function enhancement.
Learn morePT-141
An FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder in premenopausal women.
Learn moreACTH
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Learn moreBeta-Endorphin
The body's natural opioid peptide involved in pain modulation, stress response, and reward, mediating the 'runner's high' and other euphoric states.
Learn more